Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. registers 2,446,707 ordinary shares for resale by a selling shareholder via Prospectus Supplement No. 1. This supplement adds the company's GAAP Q1 2026 financial statements and updates the prospectus dated March 26, 2026.
The consolidated balance sheet shows $8.5M cash and cash equivalents as of March 31, 2026 and 10,412,764 ordinary shares issued and outstanding as of March 31, 2026. The three‑month loss was $(5,896) thousand. The resale is by a selling shareholder; issuer proceeds are not received from these resales.
Evogene Ltd. reported a weak first quarter of 2026 as it invests heavily in its AI-driven small-molecule platforms while revenue fell sharply. Revenue from continuing operations was $334 thousand for the quarter ended March 31, 2026, compared with $2.343 million in the same period of 2025, leading to a gross profit of $204 thousand.
The company recorded an operating loss of $3.15 million and a net loss of $5.9 million, versus a $2.99 million loss a year earlier, reflecting higher financing expenses tied in part to warrant-related items. Cash and cash equivalents declined to $8.5 million from $12.96 million at year-end 2025, as operating and investing activities used cash despite financing inflows from a warrant inducement share issuance. Strategically, Evogene expanded its pharma activity with three new collaborations, continued progress in its AgPlenus herbicide and fungicide programs, and entered a second AI collaboration with Google Cloud, while a herbicide project with Bayer was discontinued and its assets reverted to AgPlenus.
Evogene Ltd. reports that its subsidiary Ag Plenus Ltd. (AgPlenus) and Bayer AG have decided to discontinue their joint herbicide development project, effective May 18, 2026, after determining the target protein did not meet required product criteria.
All assets previously licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus. The report is also incorporated by reference into Evogene’s effective Form F-3 and multiple Form S-8 registration statements.
EVOGENE LTD. Schedule 13G reports that Armistice Capital, LLC and Steven Boyd beneficially own 1,104,906 ordinary shares, representing 9.99% of the class as reported. The filing states Armistice Capital exercises shared voting and dispositive power over these shares pursuant to an Investment Management Agreement. The filing is dated 05/15/2026 and cites a position as of 03/31/2026.
Evogene Ltd. executive Ravzin Polina, VP Finance, reported existing holdings of stock options on a Form 3. These options cover a total of 20,000 underlying ordinary shares with exercise prices ranging from 0.945 to 12.210 and expiration dates between 2032 and 2036, reflecting previously granted equity compensation that vests quarterly over four years for recent grants.
Evogene Ltd. reported that it received a Nasdaq notice that its ordinary shares no longer meet the $1.00 minimum bid price required under Nasdaq Rule 5550(a)(2) after trading below this level for 30 consecutive business days. The company has 180 calendar days, until September 28, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days.
Evogene’s shares will continue trading on the Nasdaq Capital Market under the symbol EVGN during this cure period, and its Tel Aviv Stock Exchange listing is unaffected. The company states that maintaining its Nasdaq listing is a key priority and that, if needed, it may consider actions such as a reverse stock split or other alternatives to restore compliance.
Evogene Ltd. registers 5,076,924 ordinary shares for resale by a selling shareholder, representing the shares issuable upon exercise of 5,076,924 ordinary warrants issued in an induced warrant exercise transaction completed on February 11, 2026.
The prospectus states the company will receive $6.35 million if the warrants are exercised in full for cash, but will not receive proceeds from secondary sales by the selling shareholder. The filing lists 9,893,764 ordinary shares outstanding as of March 15, 2026 as context, and discloses a 4.99% beneficial ownership limitation applicable to the warrants.
Evogene Ltd. registers resale of 2,446,707 ordinary shares to cover shares issued or issuable upon exercise of previously issued warrants; these shares may be sold by the Selling Shareholder from time to time.
The company will not receive proceeds from resales under this prospectus. Evogene received $3,384,616 in gross cash from the induced warrant exercise. Shares outstanding were 9,893,764 ordinary shares as of March 15, 2026.